Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) AI Stock Analysis

• Market Cap: HK$4.52B
• Dividend Yield: 1.17%
• Average Volume (3M): 19.32K
• Price to Earnings (P/E): 20.3
• Beta (1Y): 0.09
• Revenue Growth: 11.23%
• EPS Growth: 20.39%
• Country: HK
• Employees: 1,735
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.23
• Shares Outstanding: 104,213,394
• 10 Day Avg. Volume: 17,140
• 30 Day Avg. Volume: 19,320
• PEG Ratio: 4.42
• Price to Book (P/B): 2.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 194.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$33.68
• Price Target Upside: 31.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 66 Neutral
• Price Target: ―

Shanghai Kindly Medical Instruments Co., Ltd. Class H's stock score is driven primarily by its strong financial performance, highlighted by robust revenue growth and a solid balance sheet. Despite these strengths, technical analysis reveals weak momentum and bearish trends, while valuation metrics suggest the stock is fairly valued, limiting potential for significant upside. Cash flow challenges remain a concern, impacting the overall score.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Kindly Medical Instruments Co., Ltd. engages in the research and development, manufacture, and sale of cardiovascular interventional medical devices in Mainland China, Europe, the United States, and internationally. The company offers interventions products, which includes guiding catheter used to provide a channel for introducing balloon catheter, guidewire or other treatment devices; micro catheter to support the placement of guide wires; guidewire used in percutaneous transluminal angioplasty (PTA) surgical procedures; angiography catheter used to inject and infuse contrast media and fluid; and Y-connector pack used in PTCA surgery. It also provides inflation device used to inflate the balloon of dilating the vessel or placing the stent in the vessel; manifold for single use; manifold kit; pressure bandage used to assist compression hemostasis; angiography syringe for single use; stopcocks used for pressure monitoring tubing during surgery; sterile seldinger needle used to puncture into the artery; introducer set; pressure transducer for single use; extension tube for pressure monitoring; and introducer tool kit used in percutaneous vertebroplasty. In addition, the company offers medical accessories, such as check value, needle free connector, male Luer locks, bi-stopper, Heparian cap, flush device, and flow regulator; other products, including joint intervention kit, disposable respirator masks, vaginal dilator used during a vaginal examination, foley catheter, infusion pumps, disposable automatic umbilical cord clamps, infusion connector and accessory for single use, and burette infusion sets without a needle. It serves medical device manufacturers and other customers. The company was founded in 2006 and is headquartered in Shanghai, China. Shanghai Kindly Medical Instruments Co., Ltd. is a subsidiary of Shanghai Kindly Enterprise Development Group Co., Ltd.

How the Company Makes Money

Shanghai Kindly Medical Instruments Co., Ltd. generates revenue through the sale of its diverse range of medical devices to hospitals, clinics, and healthcare providers both domestically and internationally. The company's key revenue streams include direct sales of its products to medical institutions and partnerships with distributors who facilitate the broader reach of its products in different regions. Additionally, the company invests in research and development to innovate and expand its product offerings, which helps maintain its competitive edge and supports sustained revenue growth. Strategic collaborations with other medical technology firms and participation in healthcare exhibitions also contribute to its market presence and earnings.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai Kindly Medical Instruments Co., Ltd. Class H demonstrates strong financial performance with robust revenue growth and high profitability margins. The balance sheet is solid with low leverage, reducing financial risk. However, cash flow shows room for improvement, reflecting potential challenges in cash generation from operations.

Income Statement

Shanghai Kindly Medical Instruments Co., Ltd. Class H has demonstrated strong income statement performance with a consistent upward trajectory in revenue growth, showing an impressive revenue growth rate from 2023 to 2024 at 13.15%. Gross profit margin remains robust at approximately 63.11%, indicating effective cost management. The net profit margin also improved, reaching 22.53% in 2024, reflecting enhanced profitability. The company maintains healthy EBIT and EBITDA margins at 25.38% and 29.98%, respectively, showcasing operational efficiency. The key strength lies in sustained revenue growth and high profitability margins, although the company should monitor any future fluctuations in margins.

Balance Sheet

The balance sheet of Shanghai Kindly Medical Instruments Co., Ltd. Class H reveals a strong financial position with an equity ratio of 78.51% in 2024, indicating a solid equity base relative to total assets. The debt-to-equity ratio remains low at 0.14, suggesting minimal leverage and reduced financial risk. Return on equity improved to 10.82%, reflecting enhanced returns for shareholders. The company benefits from a strong equity position and low leverage, which contributes to financial stability and mitigates risk.

Cash Flow

Cash flow analysis for Shanghai Kindly Medical Instruments Co., Ltd. Class H shows areas for improvement. The operating cash flow to net income ratio is low due to operating cash flow being unavailable in 2024. Free cash flow remains a concern with fluctuations observed in prior years, indicating potential challenges in cash generation from operations. However, the company has managed to maintain a positive free cash flow in earlier periods, suggesting potential for recovery in cash flow generation. Focus should be placed on enhancing cash flow efficiency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
851.95M	752.84M	585.88M	464.68M	358.43M
	Gross Profit
537.66M	438.07M	332.49M	275.75M	234.41M
	EBIT
216.21M	178.32M	129.34M	144.64M	125.35M
	EBITDA
255.43M	225.88M	159.99M	168.81M	143.23M
	Net Income Common Stockholders
191.91M	156.46M	131.71M	142.96M	121.35M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
554.51M	434.40M	528.27M	640.55M	941.59M
	Total Assets
2.26B	2.03B	1.83B	1.62B	1.42B
	Total Debt
243.69M	94.78M	48.83M	13.40M	1.73M
	Net Debt
-278.27M	-328.89M	-469.44M	-627.15M	-868.40M
	Total Liabilities
473.39M	351.25M	273.23M	183.63M	95.04M
	Stockholders Equity
1.77B	1.65B	1.51B	1.40B	1.31B
Cash Flow		Free Cash Flow
59.80M	-53.05M	-62.75M	-205.07M	7.92M
	Operating Cash Flow
225.54M	178.15M	180.46M	72.76M	95.71M
	Investing Cash Flow
-187.31M	-283.81M	-316.18M	-268.08M	-221.87M
	Financing Cash Flow
56.97M	8.06M	9.72M	-31.07M	-27.95M

Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 25.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Negative. The current price of 25.7 is above the 20-day moving average (MA) of 25.55, below the 50-day MA of 26.34, and below the 200-day MA of 27.55, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 42.47 is Neutral, neither overbought nor oversold. The STOCH value of 79.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1501.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1501	66 Neutral	HK$4.52B	20.32	11.24%	1.17%	11.23%	20.39%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
LVZPF		$4.20B	11.87	14.56%	5.03%	―	―
1383		HK$298.29M	―		―	―	―
SHTDF		$7.42B	6.95	9.19%	5.60%	―	―
SHWGF		$3.30B	11.48	8.95%	3.60%	―	―
2198	54 Neutral	HK$2.04B	3.39	11.49%	―	47.32%	492.76%

Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events

Shanghai INT Medical Instruments Co., Ltd. Announces AGM Results and Board Appointments

Shanghai INT Medical Instruments Co., Ltd., a company incorporated in China, held its annual general meeting for 2024 on May 23, 2025. The meeting, chaired by Dr. Liang Dongke, resulted in the approval of all resolutions, including the re-election and appointment of directors and supervisors, and the election of the chairman for the fourth session of the board and supervisory committee. The unanimous approval of the company’s reports and financial statements reflects strong shareholder support and positions the company for continued stability and governance.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments Announces Board Composition

Shanghai Kindly Medical Instruments Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and decision-making processes, which could influence stakeholders’ perspectives on the company’s future operations.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments to Acquire Controlling Stake in Target Company

Shanghai Kindly Medical Instruments Co., Ltd., a company incorporated in the People’s Republic of China, has entered into a Formal Acquisition Agreement to acquire a controlling stake in a target company. The acquisition involves purchasing 81.83% equity interest in the target company for approximately RMB512.84 million, with Shanghai Kindly Medical Instruments acquiring a 51.70% controlling stake. This transaction will result in the target company becoming a non-wholly owned subsidiary, and further capital injection is planned. The acquisition is classified as a discloseable transaction under the Listing Rules, requiring reporting and announcement.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments Announces 2025 AGM Agenda

Shanghai Kindly Medical Instruments Co., Ltd. has announced its upcoming annual general meeting scheduled for May 23, 2025. The meeting will address several resolutions, including the approval of the 2024 financial reports, re-elections of board members, and the appointment of auditors. These decisions are crucial for maintaining the company’s governance and operational continuity.

Shanghai Kindly Medical Instruments Announces Board Re-Elections and Strategic Guarantee Provision

Shanghai Kindly Medical Instruments Co., Ltd. has announced the proposed re-election and appointment of directors and supervisors for its fourth session of the Board and Supervisory Committee, coinciding with the expiration of the current terms at the upcoming annual general meeting. Additionally, the company has resolved to provide a guarantee to a target company following its acquisition, indicating a strategic move to strengthen its market position and operational capabilities.

Shanghai Kindly Medical Instruments Reports Strong 2024 Financial Results

Shanghai Kindly Medical Instruments Co., Ltd. reported a significant financial performance for the year ended December 31, 2024, with a 13.17% increase in revenue to RMB851.95 million, driven by heightened market demand and an expanded customer base. The company’s gross profit and profit for the year also saw substantial growth, with gross profit margin rising to 63.11% and profit increasing by 24.03% to RMB190.05 million, reflecting strong operational efficiency and market positioning.